BLOC1S6 Knockout HAP1 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population in which the BLOC1S6 gene has been disrupted, offering a robust loss-of-function model for investigating the biogenesis of lysosome-related organelles. This product is derived from the HAP1 cell line using CRISPR/Cas9-mediated gene disruption to create a heterogeneous pool of cells with targeted inactivation of BLOC1S6, enabling studies on intracellular trafficking pathways without the limitations of clonal variability. The polyclonal format captures a range of knockout efficiencies, providing a physiologically relevant model system for high-throughput screening and detailed mechanistic analyses in a near-haploid background.
HAP1 cells are a near-haploid human chronic myeloid leukemia cell line derived from the KBM-7 parental line, widely adopted for functional genomics and haploid genetic screens. Their haploid karyotype simplifies gene-editing strategies and allows for unambiguous genotype-phenotype correlations, making them an ideal host for knockout studies. The cells retain many signaling and trafficking pathways relevant to hematopoietic and non-hematopoietic cell types, enabling translation of findings to broader biological contexts. This host background supports the investigation of BLOC1S6 function in a well-characterized, reproducible cellular system that is amenable to a wide range of molecular and cell biology techniques.
BLOC1S6 encodes a subunit of the biogenesis of lysosome-related organelles complex-1 (BLOC-1), a multi-subunit complex that mediates cargo sorting and delivery to maturing melanosomes, platelet dense granules, and other lysosome-related organelles. The BLOC-1 complex, which also includes BLOC1S1, BLOC1S2, BLOC1S3, BLOC1S4, BLOC1S5, and DTNBP1, interacts with adaptor protein complexes AP-1 and AP-3, as well as Rab GTPases Rab32 and Rab38, to regulate endosomal trafficking. BLOC1S6 functions downstream of the MITF transcription factor, which transcriptionally regulates melanogenic genes, and is essential for the proper localization of melanosome cargo proteins such as TYR, TYRP1, and OCA2. Disruption of BLOC1S6 abolishes BLOC-1 complex assembly, leading to defective melanosome biogenesis and platelet dense granule formation, hallmarks of Hermansky-Pudlak syndrome type 9.
The HAP1 knockout model recapitulates key aspects of Hermansky-Pudlak syndrome type 9, including impaired lysosome-related organelle maturation and trafficking defects, in a simplified genetic background that facilitates mechanistic dissection. The near-haploid nature of HAP1 cells ensures that a single gene disruption event is sufficient to produce a complete loss-of-function phenotype, avoiding confounding effects from diploid compensation. This model is particularly powerful for studying the interplay between BLOC-1, adaptor proteins, and Rab GTPases in melanosome biogenesis, platelet dense granule cargo loading, and pulmonary fibrosis pathways associated with Hermansky-Pudlak syndrome. It also provides a platform for small-molecule screening to identify modulators of organelle trafficking.
This product is suited for a wide array of research applications, including the study of Hermansky-Pudlak syndrome type 9, oculocutaneous albinism, and bleeding diathesis. Typical experimental approaches include immunofluorescence microscopy to assess the distribution of melanosome markers such as TYR and TYRP1, western blotting to evaluate BLOC-1 subunit expression and complex integrity, co-immunoprecipitation to probe protein?Cprotein interactions within the BLOC-1 complex, flow cytometry to quantify endosomal/lysosomal markers, and RT-qPCR to monitor MITF-driven transcriptional responses. For additional details and ordering information, please contact Ascent Research.
